妇女健康提供者对胚胎植入前遗传学检测的看法
该研究对美国马萨诸塞州一家三级学术机构的1060名妇女健康提供者进行横断面匿名在线调查,回应率22.6%(240人)。结果显示93%支持胚胎植入前遗传学检测(PGT)用于儿童期发病的基因突变,76%支持用于癌症相关遗传病,仅1.7%支持用于非疾病指征;不孕症专科医生比普通妇产科医生更支持PGT。
要点
- 93%的受访者支持PGT用于识别导致儿童期发病的基因突变。
- 76%支持PGT用于癌症相关遗传病,83%支持用于染色体非整倍体筛查。
- 仅1.7%支持PGT用于非疾病指征(如性别选择和身体特征)。
核心结论
- 在多学科妇女健康提供者样本中,整体支持PGT用于多种常见指征,不孕症专科医生支持度最高,对非疾病指征的支持率极低。
- 22.5%的妇女健康专业人员此前不了解PGT,作者认为这一比例高于预期,并提出需要加强关于该技术可用性和潜在指征的教育。
研究设计与样本
- 横断面15题匿名在线调查,对象为美国马萨诸塞州一家三级学术机构中专门从事普通妇产科、妇科肿瘤和不孕症的妇女健康提供者。
主要发现
- 调查发送给1060名提供者,240名回应(回应率22.6%)。
- 93%的受访者支持PGT用于识别导致儿童期发病的基因突变,83%支持用于染色体非整倍体筛查,76%支持用于癌症相关遗传病。
- 仅1.7%的受访者支持PGT用于非疾病相关指征,包括性别选择和身体特征。
- 与普通妇产科提供者相比,不孕症专科医生更支持PGT。
- 22.5%的受访者报告此前不了解PGT。
关键数值与推荐
- 受访者可对每个主题问题回答「是」「否」或「不确定」。
- 支持率:儿童期发病基因突变93%,染色体非整倍体筛查83%,癌症相关遗传病76%,非疾病指征1.7%。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,22.5%的妇女健康专业人员不了解PGT,表明需要就该技术的可用性和潜在指征开展更多教育。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What are the perspectives of women's health providers on the use of preimplantation genetic testing (PGT) for common medical disorders? DESIGN: A cross-sectional 15-question online anonymous survey was conducted of women's health providers specializing in general obstetrics/gynaecology, gynaecologic oncology and infertility at a tertiary care academic institution in Massachusetts, USA. Respondents could answer 'yes', 'no' or 'unsure' to each thematic question. RESULTS: The survey was sent to 1060 providers and 240 providers responded (response rate 22.6%). Overall, 93% of respondents supported the use of PGT for the identification of genetic mutations which lead to childhood-onset disease, 83% supported the use of PGT for chromosomal aneuploidy screening, and 76% supported the use of PGT for cancer-related genetic disorders. Only 1.7% of respondents supported the use of PGT for non-disease-related indications, including sex selection and physical traits. Compared with general obstetrics/gynaecology providers, infertility specialists were more supportive of PGT. In total, 22.5% of respondents reported no prior knowledge of PGT. CONCLUSIONS: In a sample of women's health providers across multiple different obstetrics/gynaecology specialties, there was overall support for the use of PGT for a variety of common indications. Infertility specialists were the most supportive, which may reflect the familiarity that these providers have with this procedure. There was an overwhelmingly non-supportive response for the use of PGT for non-disease-related indications. The percentage of medical professionals working in women's health without prior knowledge of PGT (22.5%) was higher than expected, identifying the need for more education regarding the availability and potential indications for this procedure.
引用
- Romanski PA, James KE, Sabatini ME, et al. Women's health providers' perspectives on preimplantation genetic testing. Reprod Biomed Online. 2019. PMID: 31300204. doi:10.1016/j.rbmo.2019.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。